CheckMate-77T: Perioperative nivolumab benefit for NSCLC

Share :
Published: 21 Oct 2023
Views: 163
Dr Tina Cascone - MD Anderson Cancer Center, Houston, USA

Dr Cascone updates ecancer on the findings she presented at ESMO 2023 from the phase III CheckMate-77T study, looking at patients with resectable NSCLC.

With a median follow-up of 25.4 months, in patients treated with neoadjuvant nivolumab and chemotherapy followed by surgery and adjuvant nivolumab, the risk of disease recurrence, progression or death was reduced by 42% (EFS Hazard Ratio [HR] 0.58; 97.36% Confidence Interval [CI]: 0.42 to 0.81; p=0.00025). 

The regimen also showed improvements in the pathologic complete response and major pathologic response. No new safety signals were noted with the regimen and the study is ongoing to assess its other secondary endpoint of overall survival.